Source: Cancer research and treatment [Cancer Res Treat] 2024 Apr; Vol. 56 (2), pp. 675-680. Date of Electronic Publication: 2023 Sep 25.Publisher: The Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Clinical outcomes of pomalidomide-based and daratumumab-based therapies in patients with relapsed/refractory multiple myeloma: A real-world cohort study in China.

Authors : Han X; Department of Hematology and Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.; Jiang X

Subjects: Thalidomide*/Thalidomide*/Thalidomide*/*analogs & derivatives; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/mortality

Source: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7232.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.

Authors : Ai X; Department of Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, No.241 West Huaihai Road, Shanghai, 200030, China.; Song Z

Subjects: Acrylamides*/Acrylamides*/Acrylamides*/administration & dosage ; Acrylamides*/Acrylamides*/Acrylamides*/adverse effects ; Aminoquinolines*/Aminoquinolines*/Aminoquinolines*/administration & dosage

Source: BMC cancer [BMC Cancer] 2021 Sep 16; Vol. 21 (1), pp. 1033. Date of Electronic Publication: 2021 Sep 16.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.

Authors : Djebbari F; Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Poynton M

Subjects: Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Dexamethasone/Dexamethasone/Dexamethasone/*therapeutic use

Source: Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 204-207.Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print Cited Medium: Internet ISSN: 1607-8454

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM.

Authors : Park H; Department of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.; Byun JM

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Cyclophosphamide/Cyclophosphamide/Cyclophosphamide/*administration & dosage ; Dexamethasone/Dexamethasone/Dexamethasone/*administration & dosage

Source: PloS one [PLoS One] 2022 Jan 27; Vol. 17 (1), pp. e0260113. Date of Electronic Publication: 2022 Jan 27 (Print Publication: 2022).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide.

Authors : Polton G; North Downs Specialist Referrals, Brewerstreet Dairy Business Park, Surrey, UK.; Finotello R

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Carcinoma/Carcinoma/Carcinoma/*veterinary ; Cyclophosphamide/Cyclophosphamide/Cyclophosphamide/*administration & dosage

Source: Veterinary and comparative oncology [Vet Comp Oncol] 2018 Sep; Vol. 16 (3), pp. 399-408. Date of Electronic Publication: 2018 Mar 06.Publisher: Blackwell Country of Publication: England NLM ID: 101185242 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5829

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study.

Authors : Horvath N; Department of Haematology, Royal Adelaide Hospital , Adelaide , Australia.; Spencer A

Subjects: Hematopoietic Stem Cell Transplantation*; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*administration & dosage ; Consolidation Chemotherapy/Consolidation Chemotherapy/Consolidation Chemotherapy/*methods

Source: Leukemia & lymphoma [Leuk Lymphoma] 2019 Sep; Vol. 60 (9), pp. 2122-2133. Date of Electronic Publication: 2019 Feb 19.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).

Authors : Dimopoulos MA; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.; Cavo M

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy; Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use; Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/therapeutic use

Source: Leukemia & lymphoma [Leuk Lymphoma] 2020 Mar; Vol. 61 (3), pp. 714-720. Date of Electronic Publication: 2019 Nov 05.Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Serum platelet factor 4 is a promising predictor in newly diagnosed patients with multiple myeloma treated with thalidomide and VAD regimens.

Authors : Bai J; a Department of Hematology , Second Affiliated Hospital, Xi'an Jiaotong University , Xi'an , People's Republic of China.; Wang J

Subjects: Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/blood ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/drug therapy ; Multiple Myeloma*/Multiple Myeloma*/Multiple Myeloma*/mortalityVAD protocol

Source: Hematology (Amsterdam, Netherlands) [Hematology] 2019 Dec; Vol. 24 (1), pp. 387-391.Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print Cited Medium: Internet ISSN: 1607-8454

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي

Academic Journal

Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation.

Authors : Aznab M; Internal Medicine Department, Talaghani Hospital, Kermanshah University of Medical Science, Kermanshah, Iran.; Rezaei M

Subjects: Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Immunosuppressive Agents/Immunosuppressive Agents/Immunosuppressive Agents/*therapeutic use ; Multiple Myeloma/Multiple Myeloma/Multiple Myeloma/*drug therapy

Source: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2017 Apr; Vol. 13 (2), pp. e138-e143. Date of Electronic Publication: 2015 Nov 04.Publisher: Blackwell Pub. Asia Country of Publication: Australia NLM ID: 101241430 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي